← Back

Everest Medicines Ltd

Everest Medicines Limited is a biopharmaceutical company that discovers, licenses, develops, and commercializes therapies and vaccines for critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon for immunoglobulin A nephropathy (IgAN), Xerava for infections caused by susceptible pathogens, Taniborbactam in Phase 3 for serious bacterial infections, and Etrasimod in Phase 3 for moderate-to-severe active ulcerative colitis. The company also provides Zetomipzomib in Phase 2b for immune-mediated disorders including lupus nephritis, EVER001 in Phase 1b for renal diseases, and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. In addition, it offers EVER206, a polymyxin derivative in Phase 1 for multidrug-resistant gram-negative bacterial infections. Incorporated in 2017, the company is based in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 1952.HK
United StatesChinaHong Kong SAR China
Biotech & Genomic Medicine▲2impact 4

Moderna and Merck's cancer vaccine succeeds in Phase III trial, A-share vaccine stocks hit 20% daily limit

Moderna and Merck announced preliminary positive results from the Phase III clinical trial of their mRNA personalized cancer vaccine, intismeran autogene, igniting the A-share pharmaceutical sector. On the morning of August 20, multiple vaccine stocks including Baike Biotech, Walvax Biotechnology, CanSino Biologics, Kanghua Biologics, Laimei Pharmaceutical, and Novoprotein hit the 20% daily limit, while Hong Kong-listed CanSino Biologics and Everest Medicines surged over 50% intraday. The vaccine, combined with Keytruda, was used as adjuvant therapy in more than 1,100 high-risk melanoma patients after complete surgical resection, achieving key endpoints of recurrence-free survival and reduced risk of distant metastasis. Following the announcement, Moderna's stock price soared nearly 180%, while Merck's rose over 12%.
MRNA ▲MRK ▲Walvax BioTech ▲Chengdu Kanghu… ▲Everest Medici… ▲Suzhou Novopro… ▲+1
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics ▲Competition
MRNA · Technology · Positive Moderna's mRNA cancer vaccine achieved positive Phase III results, driving stock surge.
MRK · Technology · Positive Merck's cancer vaccine with Moderna succeeded in Phase III trial, boosting its stock.
300142.CS · Demand · Positive A-share vaccine stocks hit 20% daily limit on Moderna/Merck's successful Phase III cancer vaccine trial, boosting sector sentiment.
300841.CS · Demand · Positive A-share vaccine stocks hit 20% daily limit on Moderna/Merck's successful Phase III cancer vaccine trial, boosting sector sentiment.
1952.HK · Demand · Positive Everest Medicines surged over 50% intraday as vaccine sector rallied on the news.
688137.CG · Demand · Positive Novoprotein hit 20% daily limit as vaccine stocks rallied on the trial success.
Read original ↗
红星资本局·46dRead more →
China
1952.HK▼

Everest Medicines interim revenue up 157%, Nefecon contributes nearly 80% of income

Everest Medicines disclosed its 2026 interim results, with total revenue of 1.148 billion yuan, up 157.3% year on year, and adjusted profit of 97.232 million yuan, turning from loss to profit. Sales revenue of its core product, the IgA nephropathy drug Nefecon, was 889 million yuan, contributing more than 77% of revenue, but still short of the company's previously set full-year 2026 target of 2.4 billion to 2.6 billion yuan, with the first half completing only about 37% of the lower end of the target. The company's other income came from a commercialisation services partnership with Haisen Bio, which has contributed 145 million yuan in sales revenue and 28 million yuan in profit since launching in March 2026. After the results were announced, Everest Medicines' share price fell 18.72% on the day to 23.8 Hong Kong dollars, with a total market capitalisation of 8.421 billion Hong Kong dollars.
Everest Medici… ▼
1952.HK · Capital · Negative Revenue up but Nefecon sales miss target, leading to 18.72% share drop.
Read original ↗
红星资本局·47dRead more →
1952.HK▲

Everest Medicines Closes Licensing Deal with Travere for Civorebrutinib

Everest Medicines has closed its exclusive licensing agreement with Travere Therapeutics for the development and commercialization of civorebrutinib, a potential best-in-class oral BTK inhibitor, in the U.S. and global markets outside Greater China and select Asian countries. Everest receives an upfront payment of $112.5 million and is eligible for up to approximately $1.03 billion in milestone payments across up to five indications, plus tiered royalties ranging from high single-digit to double-digit percentages on future sales.
Everest Medici… ▲TVTX ▲
1952.HK · Technology · Positive Everest closes exclusive licensing deal for civorebrutinib, a potential best-in-class BTK inhibitor, gaining rights to develop and commercialize in U.S. and global markets.
TVTX · Capital · Positive Travere receives $112.5M upfront and up to $1.03B in milestones plus royalties for licensing civorebrutinib to Everest.
Read original ↗
PR Newswire·89dRead more →
Biotech & Genomic Medicine▲

Everest Medicines' LEROCHOL BLA Accepted by China NMPA for Hypercholesterolemia

Everest Medicines announced that China's National Medical Products Administration accepted the Biologics License Application for LEROCHOL, a third-generation PCSK9 inhibitor, for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The application is based on global trials and a Phase 3 study in China, where LEROCHOL showed placebo-adjusted LDL-C reductions of 65.9% at week 12 and 67.0% for the mean of weeks 10 and 12, with over 95% of participants achieving dual Chinese lipid guideline targets. The drug is a once-monthly subcutaneous injection with up to three months of room-temperature stability. LEROCHOL has already been approved by the U.S. FDA and is under review by the European Medicines Agency. Everest Medicines expects potential approval in mainland China in 2027.
Everest Medici… ▲
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
1952.HK · Regulation · Positive China NMPA accepted BLA for LEROCHOL, a key regulatory milestone toward approval.
Read original ↗
PR Newswire·101dRead more →
1952.HK▲

Everest Medicines and Hainan Herui enter commercialization collaboration for budesonide enteric capsules

Everest Medicines and Hainan Herui have entered into a commercialization collaboration for Hainan Herui's budesonide enteric capsules, which were approved by China's National Medical Products Administration in December 2025. Under the agreement, Everest Medicines will handle commercialization in the Chinese mainland market and provide technical guidance and quality audits over manufacturing and supply. The collaboration aims to enhance patient access to the combined franchise of NEFECON and Hainan Herui's budesonide enteric capsules, and is subject to customary closing conditions.
Everest Medici… ▲
1952.HK · Demand · Positive Everest Medicines gains commercialization rights for budesonide enteric capsules in China, expanding its product portfolio and patient access.
Hainan Herui Pharmaceutical Co., Ltd. · Demand · Positive Hainan Herui partners with Everest to commercialize its approved budesonide capsules, leveraging Everest's sales infrastructure to reach more patients.
Read original ↗
PR Newswire·102dRead more →
Biotech & Genomic Medicine▲

Everest Medicines signs exclusive Asia-Pacific license with Dimerix for kidney disease drug DMX-200

Everest Medicines has signed an exclusive licensing agreement with Dimerix to develop and commercialize DMX-200 across Asia-Pacific. The deal focuses on treating serious kidney diseases such as focal segmental glomerulosclerosis, an area with significant unmet medical need. DMX-200 is already in a pivotal Phase 3 trial for that condition, giving Everest access to a late-stage program that fits its existing nephrology focus and regional commercial infrastructure. The agreement expands Everest's renal pipeline, which already includes LNZ100, Nefecon, MT1013, and EVER001, reinforcing a multi-asset approach in kidney disease therapies. Everest's shares stood at HK$26.68 at the time of the announcement, down 29.6% year to date.
Everest Medici… ▲
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › Rare Disease Competition
1952.HK · Technology · Positive Everest signs exclusive license for late-stage kidney disease drug DMX-200, expanding its renal pipeline.
Dimerix Limited · Capital · Positive Dimerix secures licensing deal with Everest, providing upfront and milestone payments for DMX-200.
Read original ↗
Simply Wall St·108dRead more →
© 2026 MarketDXAsset